Dapagliflozin Reduces Epicardial Adipose Tissue Thickness and Glucose Uptake in Type 2 Diabetes: Possible Explanation for Cardiovascular Benefits

https://pubmed.ncbi.nlm.nih.gov/38115004

Dapagliflozin treatment reduces epicardial adipose tissue thickness and glucose uptake in human type 2 diabetes, which could explain its observed cardiovascular benefits.